Search

Displaying results 5711 - 5720 of 10000 in total
  1. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  2. Drug

    Ronacaleret

    go.drugbank.com/drugs/DB05255
    Investigational

    Ronacaleret is a calcium-sensing receptor antagonist.

  3. Drug

    OSI-7904L

    go.drugbank.com/drugs/DB05457
    Investigational

    OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA).

  4. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    It was investigated as a potential treatment for various pain conditions. … Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

  5. Drug

    Hexetidine

    go.drugbank.com/drugs/DB08958
    ApprovedWithdrawn

    It is used as a 0.1% mouthwash for local infections and oral hygiene.

    Products: HEKZOTON GARGARA, 100 ML, HEKZOTON GARGARA, 200 ML
  6. Drug

    Hyaluronic acid (non-animal stabilized)

    go.drugbank.com/drugs/DB19175
    ApprovedWithdrawn

    Hyaluronic acid (non-animal stabilized) is under investigation in clinical trial NCT03460158 (Prospective Evaluation of Facial Cosmetic Procedures).

  7. Drug

    Pentafluoropropane

    go.drugbank.com/drugs/DB13117
    ApprovedWithdrawn

    Pentafluoropropane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).

  8. Drug

    Butropium

    go.drugbank.com/drugs/DB15968
    Experimental

  9. Drug

    ARC183

    go.drugbank.com/drugs/DB05124
    Experimental

    ARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity … The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid

  10. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.